There are a number of COVID-19 tests available in the market but what sets AptameX apart from the rest of them?
Achiko’s innovative AptameX technology, licensed with exclusive commercialization rights from Regenacellx.sl, is a diagnostic for COVID-19 that tests saliva samples in a novel and rapid format.
Fast and convenient: The test is completed within 15 minutes and results are sent directly to the user’s mobile phone via the Teman Sehat (Health Buddy) app, Achiko’s mobile telehealth, and digital passporting service.
High sensitivity: the AptameX reagent involves a synthetic, single-strand DNA aptamer conjugated to gold nanoparticles. The DNA aptamer binds its target, the SARS-CoV-2 spike protein (S1) with high affinity and selectivity, similar to antibodies.
New technology: Upon binding of the S1 to the DNA aptamer, gold nanoparticles are released and aggregated, changing the color of the solution. The color change cannot be seen by the naked eye but can be detected and analysed by a UV-VIS spectrophotometer (UVS).
Smartphone enabled-detection system: Teman Sehat also operates the UVS, hands the data to a cloud-based algorithm, takes the result back from the cloud and passes it on to the user’s app.
How Aptamex works in tandem with Teman Sehat
Getting tested for COVID-19 using the AptameX technology is made easier with Teman Sehat. First, download the Teman Sehat- Person app on Google Play and sign up for an account. Next, select your preferred health partner from a wide selection of accredited facilities near you then book an AptameX test. On your scheduled date, proceed to the clinic or hospital and follow the instructions as seen in the video above to pay for the test.
Using the Teman Sehat – Health app which can also be downloaded on Google Play, accredited health partners can use the app’s UV-VIS quantitative spectrophotometer detection system and mobile phone result service to process saliva samples and deliver results straight to the users’ Teman Sehat account.
Why Choose AptameX?
In an article published on Health Europa, Steven Goh, Chief Executive Officer of Achiko said: “At Achiko, we advocate moving towards proactive testing integrated into your daily routine and one that is wholly unobtrusive. It is our belief that alongside vaccination, regular testing will be required to see employees return to work with alacrity. Equally, travel will only be permitted with requisite proof of a negative COVID-19 test. The AptameX test is non-invasive and ergo that means that this additional layer of protection against the spread of the disease does not have to be intrusive. We believe that the current COVID-19 environment presents a concern for everyone, and providing a low-cost, comparably accurate testing service, is a solution to restore confidence in workplaces, amongst consumers, tourists, and within manufacturing.”
